Progression of motor symptoms in Parkinson's disease

Neuroscience Bulletin

Volumn 28, Issue 1, 2012, Pages 39-48

  Xia, Ruiping ^a   Mao, Zhi Hong ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b University of Pittsburgh   (United States)

Author keywords

Disease modification; Motor symptoms; Parkinson's disease; Progression; Treatment

Indexed keywords

ALPHA TOCOPHEROL; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE;

BRADYKINESIA; DISEASE COURSE; DISEASE SEVERITY; DYSKINESIA; FUNCTIONAL DISEASE; HORMONE SUBSTITUTION; HUMAN; INVOLUNTARY MOVEMENT; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; PARKINSON DISEASE; PATIENT CARE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE; ANIMAL; DOPAMINERGIC NERVE CELL; HYPOKINESIA; METABOLISM; MOVEMENT (PHYSIOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; TREMOR;

ANIMALS; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; HUMANS; HYPOKINESIA; MOVEMENT; MUSCLE RIGIDITY; PARKINSON DISEASE; TREMOR;

EID: 84860578177     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-012-1050-z     Document Type: Review

References (87)

1. Poewe W. Clinical measures of progression in Parkinson's disease. Mov Disord 2009, 24 Suppl 2: S671-676.
2. Poewe W, Mahlknecht P. The clinical progression of Parkinson's disease. Parkinsonism Relat Disord 2009, 15 Suppl 4: S28-32.
3. Dorsey ER CR, Thompson JP, Biglan KM, Holloway RG. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68: 384-386. (Pubitemid 46184217)
4. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5: 525-535. (Pubitemid 44262284)
5. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998, 339: 1130-1143. (Pubitemid 28465762)
6. Diaz NL, Waters CH. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Rev Neurother 2009, 9: 1781-1789.
7. Stacy M. Medical treatment of Parkinson disease. Neurologic Clinics 2009, 27: 605-631.
8. Hely MA, Morris JGL, Traficante R, Reid WGJ, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999, 67: 300-307. (Pubitemid 29392588)
9. Hely MA, Reid WGJ, Adena MA, Halliday GA, Morris JGL. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 2008, 23: 837-844.
10. Elias S, Israel Z, Bergman H. Physiology of Parkinson's disease. In: Hallett M, Poewe W (Eds.) Therapeutics of Parkinson's Disease and Other Movement Disorders. Chichester, UK: John Wiley & Sons, Ltd. 2008: 25-36.
11. Hallett M. Parkinson revisited: Pathophysiology of motor signs. Adv Neurol 2003, 91: 19-28.
12. Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008, 70: 1403-1410. (Pubitemid 351521932)
13. Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, Nicoletti V, et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. Eur J Neurol 2010, 17: 626-630.
14. Chaudhuri KR, Naidu Y. Early Parkinson's disease and non-motor issues. J Neurol 2008, 255 Suppl 5: 33-38.
15. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986, 36: 1528-1530. (Pubitemid 17175783)
16. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342: 1484-1491. (Pubitemid 30318272)
17. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000, 123 ( Pt 11): 2297-2305.
18. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328: 176-183.
19. The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996, 40: 99-107.
20. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61: 561-566.
21. Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol 2007, 30: 72-85.
22. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351: 2498-2508.
23. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999, 56: 334-337. (Pubitemid 29120231)
24. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985, 35: 522-526. (Pubitemid 15085070)
25. Fahn S, Elton RL, and members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Jenner P, et al. (Eds.). Recent Developments in Parkinson's Disease. New York: Macmillan, 1987: 153-164.
26. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006, 21: 1200-1207. (Pubitemid 44336608)
27. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010, 67: 64-70.
28. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990, 40: 1529-1534. (Pubitemid 20351344)
29. Schupbach WM, Corvol JC, Czernecki V, Djebara MB, Golmard JL, Agid Y, et al. Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating. J Neurol Neurosurg Psychiatry 2010, 81: 20-25.
30. Jellinger KA. Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999, 56: 1-29.
31. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000, 15: 692-698. (Pubitemid 30479622)
32. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurological Sci 1996, 136: 169-173.
33. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003, 18 Suppl 7: S43-51. (Pubitemid 37336928)
34. Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand[(18)F] beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999, 67: 737-741.
35. Brooks DJ, Playford ED, Ibanez V, Sawle GV, Thompson PD, Findley LJ, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992, 42: 1554-1560.
36. Spiegel J, Dorschner J, Farmakis G, Behnke S, Hellwig D, Schneider S, et al. Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2011, 17: 372-375.
37. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 1998, 39: 1143-1148. (Pubitemid 28326141)
38. Hoehn MM, Yahr MD. Parkinsonism -Onset Progression and Mortality. Neurology 1967, 17: 427-442.
39. Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994, 117 ( Pt 3): 501-507. (Pubitemid 24225898)
40. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007, 22: 938-945. (Pubitemid 46999288)
41. Duychaerts C, Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, et al. Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia Nigra. Arch Neurol 2006, 63: 584-588.
42. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114 (Pt 5): 2283-2301.
43. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005, 62: 378-382. (Pubitemid 40349472)
44. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000, 69: 308-312. (Pubitemid 30636233)
45. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. J Am Geriatr Soc 2000, 48: 938-942. (Pubitemid 30637303)
46. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5: 235-245. (Pubitemid 43238347)
47. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: A descriptive study. Lancet Neurol 2006, 5: 572-577. (Pubitemid 43867426)
48. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008, 63: 167-173. (Pubitemid 351355295)
49. Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005, 20: 726-733. (Pubitemid 41051784)
50. Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ, Grp CS. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008, 70: 2241-2247.
51. Gomez-Esteban JC, Zarranz JJ, Lezcano E, Tijero B, Luna A, Velasco F, et al. Influence of motor symptoms upon the quality of life of patients with Parkinson's disease. Eur Neurol 2007, 57: 161-165. (Pubitemid 46385602)
52. Lyons KE, Pahwa R, Troster AI, Koller WC. A comparison of Parkinson's disease symptoms and self-reported functioning and well being. Parkinsonism Relat Disord 1997, 3: 207-209. (Pubitemid 28188831)
53. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009, 24: 1641-1649.
54. Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Mac-Phee G, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007, 22: 1623-1629. (Pubitemid 47477925)
55. Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M. Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease? Mov Disord 2011.[Epub ahead of print]
56. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997, 26: 353-357. (Pubitemid 27448379)
57. Tan LC, Lau PN, Au WL, Luo N. Validation of PDQ-8 as an independent instrument in English and Chinese. J Neurol Sci 2007, 255: 77-80. (Pubitemid 46420793)
58. Politis M, Wu K, Molloy S, G Bain P, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010, 25: 1646-1651.
59. Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol 2008, 64 Suppl 2: S65-80.
60. Bassetti CL. Nonmotor disturbances in Parkinson's disease. Neurodegener Dis 2011, 8: 95-108.
61. Chan DT, Mok VC, Poon WS, Hung KN, Zhu XL. Surgical management of Parkinson's disease: a critical review. Hong Kong Med J 2001, 7: 34-39. (Pubitemid 32769477)
62. Temperli P, Ghika J, Villemure JG, Burkhard PR, Bogousslavsky J, Vingerhoets FJG. How do parkinsonian signs return after discontinuation of subthalamic DBS? Neurology 2003, 60: 78-81. (Pubitemid 36070648)
63. Robichaud JA, Pfann KD, Comella CL, Corcos DM. Effect of medication on EMG patterns in individuals with Parkinson's disease. Mov Disord 2002, 17: 950-960. (Pubitemid 36041000)
64. Vaillancourt DE, Prodoehl J, Metman LV, Bakay RA, Corcos DM. Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease. Brain 2004, 127: 491-504. (Pubitemid 38295467)
65. Powell D, Hanson N, Threlkeld AJ, Fang X, Xia R. Enhancement of parkinsonian rigidity with contralateral hand activation. Clin Neurophysiol 2011, 122: 1595-1601.
66. Shapiro MB, Vaillancourt DE, Sturman MM, Metman LV, Bakay RAE, Corcos DM. Effects of STN DBS on rigidity in Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng 2007, 15: 173-181. (Pubitemid 46957043)
67. Xia R, Markopoulou K, Puumala SE, Rymer WZ. A comparison of the effects of imposed extension and flexion movements on Parkinsonian rigidity. Clin Neurophysiol 2006, 117: 2302-2307. (Pubitemid 44333266)
68. Xia R, Sun J, Threlkeld AJ. Analysis of interactive effect of stretch reflex and shortening reaction on rigidity in Parkinson's disease. Clin Neurophysiol 2009, 120: 1400-1407.
69. Xia R. Physiological and biomechanical analyses of rigidity in Parkinson's disease. In: Rana A (Eds.). Etiology and Pathophysiology of Parkinson's Disease. Vienna, Austria: InTech, 2011: 485-506.
70. Kim MH, Cha KS, Kim HJ, Kim JS. Bilateral selective internal mammary artery angiography via right radial approach: clinical experience with newly designed Yumiko catheter. Catheter Cardiovasc Interv 2001, 54: 19-24.
71. Morrison S, Kerr G, Silburn P. Bilateral tremor relations in Parkinson's disease: Effects of mechanical coupling and medication. Parkinsonism Relat Disord 2008, 14: 298-308. (Pubitemid 351726514)
72. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008, 23: 1428-1434.
73. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2008, 23: 631-640.
74. Protas EJ, Mitchell K, Williams A, Qureshy H, Caroline K, Lai EC. Gait and step training to reduce falls in Parkinson's disease. NeuroRehabilitation 2005, 20: 183-190. (Pubitemid 43086576)
75. Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, et al. Cueing training in the home improves gaitrelated mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007, 78: 134-140. (Pubitemid 46220208)
76. Miyai I, Fujimoto Y, Yamamoto H, Ueda Y, Saito T, Nozaki S, et al. Long-term effect of body weight-supported treadmill training in Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2002, 83: 1370-1373.
77. Scandalis TA, Bosak A, Berliner JC, Helman LL, Wells MR. Resistance training and gait function in patients with Parkinson's disease. Am J Phys Med Rehabil 2001, 80: 38-43; quiz 44-36. (Pubitemid 32038014)
78. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection Trials in Parkinson's Disease: Systematic Review. Mov Disord 2009, 24: 647-654.
79. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999, 56: 529-535. (Pubitemid 29218147)
80. Olanow CW, Schapira AHV, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, et al. TCH346 as a neuroprotective drug in Parkinson"s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006, 5: 1013-1020. (Pubitemid 44709968)
81. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1: 139-154. (Pubitemid 46589347)
82. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003, 54: 93-101. (Pubitemid 36764985)
83. Olanow CW. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 2009, 72: S59-64.
84. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (The ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008, 23: 2194-2201.
85. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361: 1268-1278.
86. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 2004, 187: 455-459. (Pubitemid 38610291)
87. Mandel S, Weinreb O, Amit T, Youdim MB. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 2005, 48: 379-387. (Pubitemid 40590050)